Immunovant (IMVT) Competitors $15.46 -0.27 (-1.72%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$16.32 +0.86 (+5.56%) As of 08/8/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, MRNA, ASND, VTRS, BBIO, VRNA, BPMC, ROIV, GRFS, and LEGNShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), and Legend Biotech (LEGN). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations. Do insiders and institutionals hold more shares of IMVT or SLNO? 47.1% of Immunovant shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IMVT or SLNO? Immunovant currently has a consensus target price of $35.33, suggesting a potential upside of 128.55%. Soleno Therapeutics has a consensus target price of $113.30, suggesting a potential upside of 37.58%. Given Immunovant's higher probable upside, equities analysts clearly believe Immunovant is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is IMVT or SLNO more profitable? Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.60% -71.89% Soleno Therapeutics N/A -73.74%-56.67% Which has higher valuation and earnings, IMVT or SLNO? Soleno Therapeutics has higher revenue and earnings than Immunovant. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.74-5.64Soleno Therapeutics$32.66M134.01-$175.85M-$4.14-19.89 Does the media refer more to IMVT or SLNO? In the previous week, Soleno Therapeutics had 15 more articles in the media than Immunovant. MarketBeat recorded 18 mentions for Soleno Therapeutics and 3 mentions for Immunovant. Immunovant's average media sentiment score of 1.21 beat Soleno Therapeutics' score of 0.92 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Soleno Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, IMVT or SLNO? Immunovant has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.56, indicating that its share price is 356% less volatile than the S&P 500. SummarySoleno Therapeutics beats Immunovant on 9 of the 14 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.64B$2.99B$5.52B$9.72BDividend YieldN/A2.42%4.60%4.12%P/E Ratio-5.6417.2130.0124.75Price / SalesN/A310.81450.0597.82Price / CashN/A41.7736.7758.47Price / Book3.727.318.185.59Net Income-$413.84M-$54.43M$3.26B$265.99M7 Day Performance-1.59%0.01%6.13%5.06%1 Month Performance-11.66%0.63%0.07%0.61%1 Year Performance-47.07%8.41%36.31%22.82% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant1.5224 of 5 stars$15.46-1.7%$35.33+128.5%-47.1%$2.64BN/A-5.64120SLNOSoleno Therapeutics4.5643 of 5 stars$84.12-2.2%$108.70+29.2%+79.4%$4.33BN/A0.0030News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRNAModerna4.3302 of 5 stars$27.64+0.1%$45.61+65.0%-69.2%$10.68B$3.24B0.005,800Earnings ReportAnalyst RevisionASNDAscendis Pharma A/S3.424 of 5 stars$184.15+5.5%$223.67+21.5%+50.8%$10.67B$393.54M0.001,017Trending NewsEarnings ReportAnalyst ForecastGap UpVTRSViatris1.7916 of 5 stars$8.94+1.5%$10.40+16.3%-17.7%$10.34B$14.74B3.5532,000Trending NewsEarnings ReportDividend AnnouncementAnalyst UpgradeShort Interest ↑BBIOBridgeBio Pharma4.7237 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$8.99B$221.90M0.00400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5579 of 5 stars$105.47+0.3%$109.00+3.3%+365.4%$8.95B$42.28M0.0030Positive NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.6453 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.1503 of 5 stars$11.51+1.8%$16.50+43.4%+3.3%$7.69B$29.05M0.00860Positive NewsUpcoming EarningsGRFSGrifols3.3304 of 5 stars$10.72-0.6%$10.30-3.9%+47.9%$7.41B$7.81B9.1623,822Positive NewsAnalyst ForecastLEGNLegend Biotech3.8262 of 5 stars$38.45-0.9%$73.33+90.7%-33.8%$7.13B$627.24M0.002,609News CoverageUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies SLNO Competitors MRNA Competitors ASND Competitors VTRS Competitors BBIO Competitors VRNA Competitors BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
